Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MYGN. U.S Court of Appeals Upholds Myriad's Gene Patents
Court Finds Composition of Matter Claims for BRCA 1 and BRCA 2 Patentable
http://finance.yahoo.com/news/u-court-appeals-upholds-myriads-181942271.html
Big Board Bio updates.
StocksDiva
http://investorshub.advfn.com/StocksDiva-Bio-Bin-16112/
Watson Pharmaceuticals Inc. (NYSE:WPI) has filed suit against the U.S. FDA challenging the Agency's decision relating to Watson's entitlement to shared exclusivity for its generic version of Actos. Because of FDA's decision, Watson's abbreviated new drug application or ANDA could be delayed for up to six months. Watson said it filed suit after communications with FDA regarding its ANDA failed to resolve the dispute and permit a timely launch.
Watson maintains that FDA improperly denied the company's shared exclusivity despite the company directly following directions received from FDA concerning its Paragraph IV certification to certain patents at the time of its 2003 ANDA filing. Watson's suit would argue that the company properly filed paragraph IV certifications to certain patents for Actos listed in the FDA Orange Book in its original 2003 ANDA filing.
The FDA denied Watson's claim of shared exclusivity based on the timing of Watson's reinstatement of several of its original PIV patent certifications, which the company previously converted from a PIV to a section VIII at FDA's direction, and then reinstated back to a PIV patent certification following the settlement of patent litigation.
Watson planned to introduce its generic version of Actos on August 17, 2012, as per a settlement deal on March 10, 2010 with Takeda Pharmaceutical Company Limited and Takeda Pharmaceuticals North America. According to pre-Medicare Modernization Act Hatch Waxman rules, Watson believes it is entitled to share in the 180 day period of generic marketing exclusivity.
Bristol-Myers Squibb Company (NYSE: BMY) and Otsuka America Pharmaceutical, Inc. announced the launch of patient management programs for Sprycel^® (dasatinib) patients with a select group of specialty pharmacy providers.
The specialty pharmacies include Accredo, CuraScript, Diplomat, Biologics and Avella (formerly The Apothecary Shops). The distribution of Sprycel will remain open to other specialty and retail pharmacies.
3SBio Inc. (NASDAQ: SSRX), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the second quarter and first half ended June 30, 2012.
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ), today reported financial and operating results as at and for the second quarter ended June 30, 2012.
Cambrex Corporation (NYSE: CBM) announced that it has entered into an agreement to supply an active pharmaceutical ingredient for a customer's Phase 3 program during 2013 and 2014. Under this non-exclusive supply arrangement, Cambrex will manufacture and deliver Phase 3 and pre-launch quantities of this product candidate.
China Cord Blood Corporation (NYSE: CO), the first and largest cord blood banking operator in China, and Cordlife Group Limited (CLGL.SP) ("Cordlife"), a cord blood and tissue banking service provider listed on the Singapore Exchange Securities Trading Limited ("SGX-ST"), are fostering a close strategic partnership to offer umbilical cord blood storage services for expectant parents across Asia.
Delcath Systems, Inc. (NASDAQ: DCTH) announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for the Company's proprietary chemosaturation system for use with melphalan hydrochloride in the treatment of patients with unresectable metastatic melanoma in the liver.
Ingen Technologies, Inc. (PINKSHEETS: IGNT), an emerging medical device manufacturer with proprietary medical products for the growing $4 billion respiratory markets, announced today that the company has signed a Letter of Intent to acquire SomaLife Consulting LLC.
Myrexis, Inc. (NASDAQ: MYRX) announced today that Richard B. Brewer, 61, its Chief Executive Officer and Board member, has died after a long battle with multiple myeloma, a type of blood cancer.
Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of five additional orphan G protein-coupled receptors (GPCRs).
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter financial results for the period ended June 30, 2012.
Trovagene, Inc. (Nasdaq: TROV), a developer of transrenal molecular diagnostics, today reported its financial results for the three and six months ended June 30, 2012.
Upcoming Events
Published: Thursday, 16 Aug 2012
By: Bob Pisani
Aug. 20. 3.1 billion euros of Greek bonds due. Most seem to feel that the Greeks have the money to pay this.
Aug. 24. Spanish Cabinet meeting. Will they formally request aid from the EU? Spain will soon be receiving money for the bank bailout. There is already talk there that they will try convince EU authorities to use some of the 100 billion euros to buy Spanish sovereign bonds.
Aug. 31. Mr. Bernanke speaks at Jackson Hole...
Will there be a new program to buy Agency or mortgage-backed securities? Many think that the somewhat better economic news makes this less likely. As for the rest of the data, like jobs, well — stagnation is not a decline. Housing is getting better. And no one has yet articulated how the Fed as a group feels about acting so close to the election.
Sept. 1. ECB chief Mario Draghi at Jackson Hole. Seems like much of what he will say will depend on what, if anything, happens at the Spanish Cabinet meeting of the week before. Mr. Draghi made the procedure clear: a country must ask for aid. Then the EFSF/ESM can be activated, but only with "conditionality."
September 6: ECB meeting. We will hear of any further rate cuts, but more importantly under what conditions the ECB might revive its own bond buying program, the Securities Markets Program (SMP).
Sept. 12: German Constitutional Court rules on legality of ESM. Most feel this will pass muster, but there is some risk. If it is overturned or delayed, the burden of any request for aid from Italy or Spain would fall squarely on the shoulders of the ECB.
MGM Update: Hit $10.43 now! On track to 16/18 successful trades.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78377313&txt2find=mgm
*Refer to the Intro/iBox for more information
I'll be back in an hour or two, need to take a quick nap lol.
And down it goes :)
YO Charles !
Morning Dan :)
IDIX - Idenix Provides Update on IDX184 Clinical Development Program
Date : 08/16/2012 @ 8:00AM
Source : GlobeNewswire Inc.
Stock : Idenix Pharmaceuticals, Inc. (MM) (IDIX)
Quote : 8.31 0.0 (0.00%) @ 8:56AM
IDIX now trading $5.00 pre-market ... Ouch
Idenix Provides Update on IDX184 Clinical Development Program
IDX184 has been placed on partial clinical hold by FDA
Management to host a conference call webcast today at 8:30 am ET
Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced that the Company received verbal notice from the U.S. Food and Drug Administration (FDA) that a partial clinical hold has been placed on IDX184, the Company's nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus (HCV).
As a result of the recent occurrence of a serious cardiac-related adverse event encountered with a competitor's nucleotide polymerase inhibitor for the treatment of HCV, the FDA has expressed an interest in further reviewing the safety of IDX184 and has placed IDX184 on partial clinical hold. In previous clinical trials as well as the ongoing phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (PegIFN/RBV), there has been no evidence to date of cardiotoxicity in patients dosed with IDX184 with PegIFN/RBV beyond that seen with PegIFN/RBV alone. There are currently no patients receiving IDX184 worldwide.
The FDA has requested additional data on patients treated with IDX184. Patient safety is our main concern and Idenix will immediately begin work to comply with the FDA request and expects to submit these data to the FDA in the coming weeks. The Company intends to have an ongoing discussion with the FDA following the submission of this data.
ABOUT IDX184
IDX184 is an unpartnered, novel, liver-targeted nucleotide prodrug of 2'-methyl guanosine, which includes Idenix's proprietary liver-targeting technology. This technology enables the delivery of nucleoside monophosphate to the liver, leading to the formation of high levels of nucleoside triphosphate, potentially maximizing drug efficacy and limiting systemic side effects with low, once-daily dosing. The Company reported interim data in June 2012 for the first cohort of 31 patients from an ongoing phase IIb clinical trial of IDX184 in combination with PegIFN/RBV. Of the patients who achieved an extended rapid virologic response (undetectable levels of virus at 4 weeks and 12 weeks) and completed an additional 12 weeks of PegIFN/RBV (n=9), 100% of patients (4/4) in the 100 mg arm and 80% of patients (4/5) in the 50 mg arm achieved a sustained virologic response four weeks after the completion of treatment (SVR4).
In July 2012, an independent data safety monitoring board reviewed the safety data for this study and confirmed that the side effect profile of IDX184 combined with PegIFN/RBV is consistent with that of PegIFN/RBV alone.
ABOUT PARTIAL CLINICAL HOLD
A partial clinical hold is a delay or suspension of only part of the clinical work requested under the investigational new drug (IND) application (e.g., a specific protocol or part of a protocol is not allowed to proceed; however, other protocols or parts of the protocol are allowed to proceed under the IND). Under the partial clinical hold, Idenix cannot enroll patients into additional clinical trials until agreement is reached with the FDA on the next clinical trial design.
ABOUT IDENIX
Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical Company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection. For further information about Idenix, please refer to www.idenix.com.
CONFERENCE CALL AND WEBCAST INFORMATION
Idenix will hold a conference call today at 8:30 a.m. ET. To access the call, please dial (877) 640-9809 (U.S./Canada) or (914) 495-8528 (International) and enter passcode 22005490. A slide presentation will accompany the conference call and can be accessed on the Investor section of the Idenix website at www.idenix.com. Please log on approximately 10 minutes prior to the start of the call to ensure adequate time for any downloads that may be necessary.
A replay of the conference call and webcast will be available until August 27, 2012, by dialing (855) 859-2056 (U.S./Canada) or (404) 537-3406 (International) and enter the passcode 22005490.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, including but not limited to the statements regarding the Company's future business and financial performance. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "expect," "plans," "anticipates," "intends," "will," and similar expressions are also intended to identify forward-looking statements, as are expressed or implied statements with respect to the Company's potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184 or any other drug candidate; the successful development of novel combinations of direct-acting antivirals for the treatment of HCV; and the likelihood and success of any future clinical trials involving IDX184 or our other drug candidates. Actual results may differ materially from those indicated by such forward-looking statements as a result of risks and uncertainties, including but not limited to the following: there can be no guarantees that the Company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization; management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; changes in the Company's business plan or objectives; competition in general; and the Company's ability to obtain, maintain and enforce patent and other intellectual property protection for its product candidates and its discoveries. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. These and other risks which may impact management's expectations are described in greater detail under the heading "Risk Factors" in the Company's annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the quarter ended June 30, 2012, each as filed with the Securities and Exchange Commission (SEC) and in any subsequent periodic or current report that the Company files with the SEC.
All forward-looking statements reflect the Company's estimates only as of the date of this release (unless another date is indicated) and should not be relied upon as reflecting the Company's views, expectations or beliefs at any date subsequent to the date of this release. While Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, even if the Company's estimates change.
CONTACT: Idenix Pharmaceuticals Contacts:
Kelly Barry (617) 995-9033 (media)
Daniella Beckman (617) 224-4471 (investors)
CAT. Caterpillar, Striking Workers in Joliet, Ill., Reach Tentative Deal
http://www.newsdaily.com/stories/bre87e0xb-us-caterpillar-joliet/
Good post PS !
Tomorrow should be an interesting day
FaceBook lockout period ends tomorrow.
http://news.yahoo.com/facebook-stock-tank-again-first-lockout-period-expires-090927674.html
Facebook's sagging stock will face another test on Thursday when the first of the company's lockout periods to sell the stock will expire, freeing up some 271 million shares.
[More from Mashable: 2012 Olympics: The Social Media Winners [INFOGRAPHIC]]
Some insiders who hold stock in the company including COO Sheryl Sandberg and CFO David Ebersman, will be free to sell the stock on Aug. 16. It's unclear how many will take the option; the company's stock was down more than 46% from its IPO price Wednesday morning, when it was trading for $20.38. However, the expiration of a lockout period usually drags a company's stock price down further. When LinkedIn's and Groupon's first lockout periods ended, the companies' stock prices fell 7% and 10%, respectively.
This is the first of many expiration periods for Facebook stock. A total of 1.8 billion shares could hit the market in the next 18 months. Some 421 million shares have traded since the company went public in May. The next big dump could happen in November, when Facebook will convert restricted stock units held by many employees into actual stock.
Big Boards - Top Losers Wed Aug 15 - Source: finviz.com
[ 10%+ losers ]
TBOW Trunkbow International Holdings, Ltd. 0.89 -29.68%
CRC Chromcraft Revington, Inc. 0.92 -29.23%
MBND Multiband Corporation 1.68 -21.50%
FES Forbes Energy Services Ltd. 3.50 -19.72%
NLST Netlist Inc. 1.57 -17.37%
CTRN Citi Trends 12.53 -14.99%
CLNT Cleantech Solutions International, Inc. 2.88 -14.79%
SPLS Staples, Inc. 11.49 -14.64%
SCIL Scientific Learning Corp. 0.95 -13.64%
SWHC Smith & Wesson Holding Corporation 8.60 -11.89%
CRMB Crumbs Bake Shop, Inc 2.66 -11.63%
BSPM Biostar Pharmaceuticals, Inc. 1.30 -11.56%
CPRX Catalyst Pharmaceutical Partners Inc. 1.40 -11.39%
CSIQ Canadian Solar Inc. 2.70 -11.02%
CYOU Changyou.com Limited 21.69 -10.22%
http://stockcharts.com/c-sc/sc?s=TBOW&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CRC&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=MBND&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=FES&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=NLST&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CTRN&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CLNT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SPLS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SCIL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SWHC&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CRMB&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=BSPM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CPRX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CSIQ&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CYOU&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
Big Boards - Top Gainers Wed Aug 15 - Source: finviz.com
Top 25 charts posted.
20%+ gainers
IMH Impac Mortgage Holdings Inc. 4.19 87.05%
CFBK Central Federal Corp. 2.35 36.63%
SNFCA Security National Financial Corp. 3.49 34.23%
REGI Renewable Energy Group, Inc. 5.98 27.23%
10%-20% gainers
LEE Lee Enterprises Inc. 1.59 19.55%
LOJN LoJack Corp. 2.89 19.42%
AOSL Alpha & Omega Semiconductor, Ltd. 10.34 18.71%
AIQ Alliance Healthcare Services, Inc. 1.36 18.26%
ATEA Astea International Inc. 4.15 14.64%
FACE Physicians Formula Holdings Inc. 4.21 14.40%
KIPS Kips Bay Medical, Inc. 1.54 14.07%
CEL Cellcom Israel Ltd. 7.45 12.71%
PGRX Prospect Global Resources, Inc. 2.79 12.05%
SLCA U.S. Silica Holdings, Inc. 11.82 11.83%
HUSA Houston American Energy Corp. 1.14 11.77%
PTNR Partner Communications Company Ltd. 4.02 11.36%
ZIPR zipRealty Inc. 2.22 10.99%
PLAB Photronics Inc. 6.33 10.66%
TROX Tronox Incorporated 24.90 10.08%
5%-10% gainers
FFEX Frozen Food Express Industries Inc. 1.77 9.94%
SRPT Sarepta Therapeutics, Inc. 9.20 9.26%
BCRX BioCryst Pharmaceuticals, Inc. 3.97 9.07%
ANF Abercrombie & Fitch Co. 35.23 8.97%
PERY Perry Ellis International Inc. 22.27 8.85%
UEC Uranium Energy Corp. 2.59 8.82%
VIP VimpelCom Ltd. 10.20 8.74%
CECE CECO Environmental Corp. 8.99 8.44%
JDSU JDS Uniphase Corporation 11.56 8.24%
S Sprint Nextel Corp. 5.39 8.02%
MTSN Mattson Technology Inc. 1.08 8.00%
TXCC TranSwitch Corp. 1.08 8.00%
SGMS Scientific Games Corporation 6.69 7.90%
ES EnergySolutions, Inc 2.35 7.80%
HALO Halozyme Therapeutics, Inc. 5.99 7.73%
FBN Furniture Brands International Inc. 1.13 7.62%
HOLI Hollysys Automation Technologies, Ltd 9.03 7.50%
KIRK Kirkland's Inc. 10.99 7.43%
CHFN Charter Financial Corp. 10.00 7.41%
BMTI BioMimetic Therapeutics Inc. 3.48 7.41%
ARRY Array BioPharma, Inc. 5.23 7.39%
HK Halcon Resources Corporation 8.29 7.38%
MRGE Merge Healthcare Incorporated 3.09 7.29%
SEED Origin Agritech Limited 1.64 7.19%
GILT Gilat Satellite Networks Ltd. 2.85 7.14%
IMGN Immunogen Inc. 13.95 6.90%
TRLG True Religion Apparel Inc. 22.83 6.68%
DNDN Dendreon Corp. 4.97 6.65%
PCS MetroPCS Communications, Inc. 9.79 6.64%
HUN Huntsman Corporation 14.48 6.63%
STRI STR Holdings, Inc. 3.38 6.62%
PEGA Pegasystems Inc. 27.57 6.57%
OMG OM Group Inc. 17.37 6.56%
ANAD Anadigics, Inc. 1.14 6.54%
SYRG Synergy Resources Corporation 2.94 6.52%
TTWO Take-Two Interactive Software Inc. 9.38 6.47%
VVTV ValueVision Media Inc. 1.83 6.40%
CBEY Cbeyond, Inc. 8.41 6.32%
WAC Walter Investment Management Corp. 26.43 6.27%
PRSC Providence Service Corp. 11.07 6.14%
MOV Movado Group, Inc. 27.87 6.09%
LEAP Leap Wireless International Inc. 5.93 6.08%
MGIC Magic Software Enterprises Ltd. 4.55 6.06%
NOK Nokia Corporation 2.64 6.02%
RNF Rentech Nitrogen Partners, L.P. 33.72 6.00%
ARX Aeroflex Holding Corp. 5.83 6.00%
NCIT NCI, Inc. 7.95 6.00%
VITC Vitacost.com, Inc. 5.35 5.94%
KVHI KVH Industries Inc. 13.39 5.77%
DTLK Datalink Corp. 7.97 5.70%
MHR Magnum Hunter Resources Corp. 4.28 5.68%
UIS Unisys Corporation 20.47 5.62%
FIRE Sourcefire, Inc. 49.45 5.59%
AHS AMN Healthcare Services Inc. 7.39 5.57%
ALN American Lorain Corporation 1.14 5.56%
GMCR Green Mountain Coffee Roasters Inc. 24.11 5.51%
HRC Hill-Rom Holdings, Inc. 27.70 5.44%
SPRD Spreadtrum Communications Inc. 18.22 5.44%
FNSR Finisar Corp. 14.48 5.39%
CPSS Consumer Portfolio Services, Inc. 2.35 5.38%
TTEC TeleTech Holdings Inc. 17.00 5.33%
FSLR First Solar, Inc. 21.10 5.29%
FXEN FX Energy Inc. 7.97 5.28%
INVN InvenSense, Inc. 13.99 5.27%
SGMO Sangamo Biosciences Inc. 5.43 5.23%
TST TheStreet, Inc. 1.41 5.22%
CALD Callidus Software Inc. 4.24 5.21%
AERL Asia Entertainment & Resources Ltd. 3.67 5.16%
FLOW Flow International Corp. 3.47 5.15%
KOPN Kopin Corp. 3.48 5.14%
MEA Metalico Inc. 2.28 5.07%
CADX Cadence Pharmaceuticals Inc. 3.97 5.03%
http://stockcharts.com/c-sc/sc?s=IMH&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CFBK&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SNFCA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=REGI&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LEE&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LOJN&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=AOSL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=AIQ&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ATEA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=FACE&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=KIPS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CEL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PGRX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SLCA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=HUSA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PTNR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ZIPR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PLAB&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=TROX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=FFEX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SRPT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=BCRX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ANF&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PERY&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=UEC&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
Cisco Beats on Earnings, Raises Quarterly Dividend to 14 Cents a Share From 8 Cents.
>> Update
Symbol %Change Last High Change
FACE +14.70% 4.221 4.24 +0.541
CEL +11.95% 7.4001 7.45 +0.7901
ANF +10.11% 35.60 35.95 +3.27
SGMS +8.71% 6.7399 6.75 +0.5399
JDSU +8.52% 11.59 11.79 +0.91
ARRY +7.60% 5.2399 5.24 +0.3699
REGI +7.23% 5.0399 5.54 +0.3399
HALO +6.29% 5.91 6.00 +0.35
AERL +4.87% 3.66 3.75 +0.17
GALE +3.95% 1.58 1.61 +0.06
UIS +3.72% 20.10 20.15 +0.72
GMCR +3.59% 23.67 23.95 +0.82
EZCH +3.51% 29.23 29.30 +0.99
AVEO +2.98% 8.99 9.06 +0.26
RLD +2.80% 10.64 10.70 +0.29
CORT +2.56% 3.21 3.23 +0.08
MDRX +2.49% 11.51 11.59 +0.28
AXTI +2.22% 3.23 3.27 +0.07
SFUN +2.09% 14.16 14.56 +0.29
MOTR halted 11:22am - Additional Information Requested by NASDAQ
Trading is halted pending receipt of additional information requested by NASDAQ.
Posted earlier:
Motricity Plans to Modify Its Rights Offering
The Company Suspends Rights Offering Pending Modification
GlobeNewswirePress Release: Motricity, Inc. – 2 hours 10 minutes ago
BELLEVUE, Wash., Aug. 15, 2012 (GLOBE NEWSWIRE) -- Motricity, Inc. (MOTR) today announced that it has determined that it is advisable and in the best interests of the Company (taking into account, among other things, stockholder comments and tax considerations) to modify the composition of the units in its ongoing rights offering, which was commenced on July 23, 2012 and scheduled to expire at 5:00 pm Eastern Time on August 17, 2012 ("Rights Offering"). The Company has suspended the Rights Offering and has requested NASDAQ to suspend the trading of the rights issued in the Rights Offering, which have been trading on the NASDAQ Global Select Market under the symbol "MOTRR". No exercise of rights issued in the Rights Offering will be accepted. Any subscription payments received by the Company in connection with the Rights Offering will be refunded without interest or penalty.
The Company plans to resume the Rights Offering after the units to be sold in the Rights Offering have been modified and a registration statement describing such modification has been filed with the Securities and Exchange Commission and declared effective.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company. Any such offer, if made, will be made pursuant to a prospectus included in a registration statement filed with and declared effective by the SEC.
About Motricity
Motricity empowers mobile operators, brands and advertising agencies to maximize the reach and economic potential of the mobile ecosystem through the delivery of relevance-driven merchandising, marketing and advertising solutions. Motricity leverages advanced predictive analytics capabilities to deliver the right content, to the right person at the right time. Motricity provides their entire suite of mobile data service solutions through one, integrated, highly scalable managed service platform. Motricity's unique combination of technology, expertise and go-to-market approach delivers return-on-investment for its mobile operator, brand and advertising agency customers. For more information, visit www.motricity.com.
The Motricity, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7813
Safe Harbor and Forward-Looking Statements
Statements made in this release that express Motricity's or its management's intentions, indications, beliefs, expectations, guidance, estimates, forecasts or predictions of the future constitute forward-looking statements, as defined by the Private Securities Litigation Reform Act of 1995, and relate to matters that are not historical facts. They include, without limitation, statements about Motricity's plans to resume the Rights Offering. These statements represent beliefs and expectations only as of the date of this press release and are subject to certain risks and uncertainties that may cause the Company's actual results to differ materially from those discussed in a forward looking statement. For example, the Company cannot assure that a registration statement will be filed with or declared effective by the SEC, that it will resume the Rights Offering on a timely basis, if at all, or that the Rights Offering, if resumed, will be successful. The Company may elect to update forward-looking statements but it expressly disclaims any obligation to do so, even if its beliefs and expectations change.
Contact:
Investor and Media Contact:
Alex Wellins
The Blueshirt Group
(415) 217-5861
alex@blueshirtgroup.com
Today's tankers:
AEZS (-9.61%)
CUR (-22.73%)
FES (-19.72%)
GBG (-45.46%)
JAG (-11.5%)
NLST (-23.16%)
SPLS (-14.31%)
>> Early movers ...
Symbol %Change Last High Change
FACE +15.22% 4.24 4.24 +0.56
REGI +12.13% 5.27 5.54 +0.57
ANF +10.42% 35.70 35.70 +3.37
JDSU +8.16% 11.5511 11.70 +0.8711
HALO +4.86% 5.83 5.86 +0.27
CEL +4.69% 6.92 6.94 +0.31
GALE +4.61% 1.59 1.61 +0.07
AERL +4.60% 3.6505 3.75 +0.1605
SFUN +3.89% 14.41 14.56 +0.54
ARRY +3.49% 5.04 5.07 +0.17
NOK +3.22% 2.5701 2.59 +0.0801
GMCR +2.98% 23.53 23.74 +0.68
OTT +2.69% 2.67 2.75 +0.07
UIS +2.43% 19.85 19.97 +0.47
ARNA +2.07% 8.431 8.86 +0.171
AAPL Update: hit $638 yesterday! $2 shy from my sell target.
AAPL rallying back up (still holding). I'm confident I'll get my $640 sell target in the near term, especially when the new iPhone arrives.
*Refer to the Intro/iBox for more information.
A "windows phone"...really? Last I check, the so called windows phone flopped big time. The iPhone is still racking up all the sales.
*I have no position in the stock.
Nokia Promises New Windows Phone Coming Soon
Published: Wednesday, 15 Aug 2012
By: Reuters
Nokia Chief Executive Stephen Elop promised to unveil a new smartphone using Microsoft's latest Windows 8 software soon, raising the prospect it will be launched in early September before rival Apple promotes its new iPhone.
Nokia [NOK 2.49 (---) ], which is fighting for survival after losing out to rivals in the lucrative smartphone business, is due to hold a trade show in Helsinki on September 5-6, just before an Apple [AAPL 631.69 (---) ] event on September 12 where the U.S. competitor could announce a redesigned iPhone.
Nokia, the world's second-largest cellphone maker, has not commented on what it will announce at the Nokia World event, but business magazines have said it will unveil the new Windows 8 [MSFT 30.13 (---) ] smartphones.
Elop, in Oslo for a meeting with Telenor [TEQ-FF 13.99 -0.063 (-0.45%)] Chief Executive Jon Fredrik Baksaas, did not deny a September launch but would only say Windows 8 smartphones would be released "relatively near term."
Nokia shares, which have been trading near all-time lows, rose sharply after Elop's comments and traded up 7.5 percent.
Elop, who was brought in from Microsoft in September 2010 to lead the company's battle against increasingly dominant Apple and Samsung [SAMC-LN --- UNCH ()], said he was sticking to his strategy of using Microsoft software despite the limited success of Windows Phones so far.
Nokia decided in early 2011 to ditch its home-grown Symbian software for a deal with Microsoft, aiming to catch up with Apple and Google [GOOG 668.66 (---) ] in smartphones.
"I don't think about rewinding the clock and thinking about competing elsewhere," he told reporters.
"In today's war ... (between) Android, Apple and Windows, we are very clear, we are fighting that with the Windows phone."
Nokia lost 1.53 billion euros in the second quarter and sold just 4 million Windows phones in the period, well short of Apple's sales of 26 million iPhones and Samsung's 50 million smartphones.
Oh Lord ! ... lol
US Industrial Output Grows at Fastest Pace Since April
Published: Wednesday, 15 Aug 2012
By: Reuters
U.S. industrial output expanded last month at the fastest pace since April and manufacturing notched another solid advance, hinting at underlying resilience in an economy that has struggled to establish momentum.
Industrial production increased by 0.6 percent in July, the Federal Reserve said on Wednesday, beating a 0.5 percent gain forecast by a Reuters poll of economists and compared with a downwardly revised increase of 0.1 percent in June.
Factory production was up 0.5 percent in the month and utilities output rose a solid 1.3 percent, snapping back from a sharp 3.3 percent decline in June. Mining production rose 1.2 percent.
Capacity utilization, a measure of how fully firms are using their resources, was 79.3 percent, just beating forecasts and advancing from 78.9 percent in June.
Morning Dan! I might pass out due to sleep deprivation in an hour, so I'll try to get as much done before that happens lol...I was celebrating a buddy's birthday yesterday...it went on a little longer than I expected.
CPRX - Catalyst Pharmaceutical Partners Announces Second Quarter 2012 Financial Results
CORAL GABLES, Fla., Aug. 15, 2012 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc. (Nasdaq:CPRX) today announced its financial results for the second quarter and six months ended June 30, 2012. For the three months ended June 30, 2012, the Company reported a net loss of $289,080, or $0.01 per basic and diluted share, compared to a net loss of $1,394,151, or $0.06 per basic and diluted share, for the same period in 2011. For the six months ended June 30, 2012, the Company reported a net loss of $1,378,266, or $0.05 per basic and diluted share, compared to a net loss of $2,911,287, or $0.14 per basic and diluted share, for the same period in 2011.
Research and development expenses for the second quarter of 2012 were $532,741, compared to $905,635 in the second quarter of 2011. Research and development expenses for the six months ended June 30, 2012 were $1,260,068 compared to $1,809,588 for the first six months of 2011. Research and development expenses decreased when compared to the same period in 2011, as expenses incurred during the six month period ended June 30, 2011 included pre-clinical studies and drug development activities for CPP-115 in connection with the submission of an IND for CPP-115 (which occurred during the fourth quarter of 2011). General and administrative expenses for the second quarter of 2012 totaled $534,623, compared to $491,828 in the second quarter of 2011. General and administrative expenses for the first six months of 2012 totaled $1,172,006 compared to $1,107,125 in the first six months of 2011. Other income for the second quarter and six months ended June 30, 2012 was $778,284 and $1,053,808, respectively, compared to $3,312 and $5,426 for the same periods in 2011. These fluctuations were primarily due to non-cash changes in the fair value of the Company's outstanding warrants liability.
As a development-stage specialty pharmaceutical company, Catalyst had no revenues in either the second quarter of 2012 or first six months of 2012.
At June 30, 2012, the Company had cash and cash equivalents of $7.5 million and no debt. Catalyst believes that its existing cash and cash equivalents will be sufficient to fund its currently ongoing CPP-109 and CPP-115 research and development activities, and to continue its operations through the first quarter of 2014.
Recent Accomplishments and Upcoming Events
Completed enrollment in the CPP-109 Phase II(b) clinical trial for the treatment of cocaine addiction in May 2012
Reported positive results from Phase I(a) clinical study of CPP-115 in May 2012
Closed an underwritten offering with net proceeds of approximately $3.9 million in May 2012
Presented CPP-115 progress at the 2012 College on Problems of Drug Dependence Symposium in June 2012
Published scientific paper describing the ocular safety of short-term vigabatrin treatment for cocaine addiction in online edition of American Journal of Ophthalmology in June 2012
Expect to report top-line results of CPP-109 Phase II(b) clinical trial around September 30, 2012
Expect to initiate investigator-sponsored CPP-109 Tourette Syndrome proof-of-concept study in the third quarter of 2012
Stock futures dip ahead of data
U.S. Day Ahead: Cisco's Chambers set to sing European blues
Tue, Aug 14 2012
Traders work on the floor of the New York Stock Exchange August 14, 2012. REUTERS/Brendan McDermid
By Chuck Mikolajczak
NEW YORK | Wed Aug 15, 2012 7:23am EDT
(Reuters) - Stock index futures edged lower on Wednesday ahead of a report on inflation and a regional manufacturing survey which may provide clues on the state of the economy.
The S&P 500 index has stalled near early May highs after showing gains in seven of the past nine sessions, as the benchmark index has not moved more than 0.22 percent in either direction over the past five sessions and volume has declined in what is normally a seasonally slow period.
At 8:30 a.m. (1230 GMT) investors will look to the consumer price index for July and the Empire State manufacturing survey for August. Economists in a Reuters survey expect a 0.2 percent increase in CPI compared with a flat reading in June while the manufacturing survey's main index is expected to show a reading of 6.5 versus the 7.39 in July.
Data expected later in the session includes industrial production and capacity utilization data for July at 9:15 a.m. (1315 GMT) and the National Association of Home Builders/Wells Fargo August housing market index at 10 a.m. (1400 GMT).
Economists in a Reuters survey expect a 0.5 percent rise in production and a reading of 79.2 percent for capacity utilization. The housing market index is expected to show a 35 reading, identical to the July data.
S&P 500 futures fell 2.9 points and were below fair value, a formula that evaluates pricing by taking into account interest rates, dividends and time to expiration on the contract. Dow Jones industrial average futures lost 16 points, and Nasdaq 100 futures dropped 4.5 points.
Staples Inc (SPLS.O) dropped 10.8 percent to $12 in light premarket trade after the office supply chain reported lower-than-expected quarterly revenue on weak demand in North America, Europe and Australia and forecast flat sales for the fiscal year.
Other S&P 500 companies scheduled to post earnings on Wednesday include Agilent Technologies Inc (A.N), Abercrombie & Fitch Co (ANF.N), Cisco Systems (CSCO.O), Limited Brands (LTD.N), NetApp Inc (NTAP.O) and Target Corp (TGT.N).
European shares fell from four-month highs, led by basic resources stocks after a bearish update from miner ENRC (ENRC.L). .EU
Asian shares fell as investors booked gains from recent rallies after data showing strong U.S. retail sales and Germany and France avoiding a contraction last quarter calmed sentiment, with weak euro zone growth sustaining stimulus hopes.
(Reporting by Chuck Mikolajczak; Editing by Chizu Nomiyama)
Stock Market News for August 15, 2012
ZacksBy Zacks Equity Research | Zacks – 2 hours 40 minutes ago
An encouraging retails sales reading coupled with disappointing inventory growth left the benchmarks struggling for a definite direction yesterday. While the Dow managed paltry gains, S&P 500 and Nasdaq slipped meager points. Negligible movement in the benchmarks came along with another day of low volumes and investors opted to term it a ‘fatigued market’.
The Dow Jones Industrial Average (:DJI) ended just 2.71 points or 0.02% higher at 13,172.14. The Standard & Poor 500 (S&P 500) slipped a negligible 0.01% or 0.18 point to finish yesterday’s trading session at 1,403.93. The tech-laden Nasdaq Composite Index was down 0.2% to end at 3,016.98. The fear-gauge CBOE Volatility Index (:VIX) jumped 8.4% to settle at 14.85. Volumes were yet again low with consolidated volumes of roughly 5.16 billion shares on the New York Stock Exchange, Nasdaq and American Stock Exchange, lower than last year's daily average of 7.84 billion shares. The advancing and declining stock on the NYSE were almost even; as for 47% stocks that gained, 49% stocks closed lower.
With not too much of negative around yesterday, interestingly the fear-gauge index made a sharp movement upward. However, one might not read too much into it, as on Monday the index had dropped to five-year low while the markets ended in the red. Generally, VIX moves in the opposite direction of the market and a drop in the fear-gauge index reflects improving investors confidence and vice versa. On Monday, certain market onlookers had opined that investors were not aggressively bothered about the negative situation.
Low volume is another trend that the Street is witnessing over the past few days. On Tuesday also, volumes were sharply lower than average. With regard to this, a cautious stance dominating the mood has largely kept investors away from betting big. Strategists also opined that the volumes will pick up only after investors are back from summer holidays.
Speaking about the cautious stance, investors are awaiting concrete actions by the central banks, and they have focused less on the limited number of headlines. Yesterday too, benchmarks were reluctant to move on either side following a surprisingly encouraging retail sales data and dismal growth in inventories.
Looking at the retail sales data, the Commerce Department reported that it sprung 0.8% in July. This was the best jump since February this year. Also, the 0.8% jump far outpaced the consensus estimates of a 0.3% gain. Separately, Labor Department reported the U.S. producer prices index to have increased 0.3% in July, up from 0.1% gain in June and consensus estimates of 0.2% increase.
The retail sales data was encouraging news not only for the retail sector but obviously for the overall economy as well. The retail stocks enjoyed gains yesterday and the SPDR S&P Retail (XRT) was up 0.2%. Among the retailers, Target Corporation (NYSE:TGT), PriceSmart, Inc. (NASDAQ:PSMT), Wal-Mart Stores, Inc. (NYSE:WMT), Macy's, Inc. (NYSE:M) and the The Bon-Ton Stores, Inc. (NASDAQ:BONT) jumped 1.4%, 0.4%, 0.8%, 1.0% and 3.1%, respectively. Another retailer, The Home Depot, Inc. (NYSE:HD) jumped 3.6% as not only did its quarterly results manage to surpass the Street’s estimates, but the company also upped its guidance.
However the positive mood from this data was offset by a separate report on business inventories. The Commerce Department noted a mere 0.1% rise in business inventories in June to $1.58 trillion. This was lower than May’s growth of 0.3%, but was in line with the consensus estimates. Moreover, the report also noted a 1.1% drop in sales, the largest decline since March 2009.
VIP - VimpelCom Second-Quarter Profit Almost Doubles, Beats Estimate
By Anatoly Temkin - Aug 15, 2012 3:13 AM ET
VimpelCom Ltd. (VIP) boosted profit more than analysts estimated in the second quarter as the Russian mobile operator expanded in Asia and Africa after combining with Italy’s Wind Telecom SpA.
Net income climbed 83 percent to $488 million from a pro- forma $267 million in the same period last year, VimpelCom said today in a statement. That beat an average estimate of $316 million from five analysts surveyed by Bloomberg.
Emerging market operations helped offset weak sales and profits in Europe and North America, according to the company. VimpelCom’s biggest market remains Russia, where the government is pushing billionaire shareholder Mikhail Fridman for an out- of-court settlement with Telenor ASA (TEL) about the size of the Norwegian company’s stake.
“The company is heading in the right direction,” Konstantin Belov, an analyst at UralSib Financial said by phone from Moscow, before the results. “There are signs that the conflict between shareholders may be solved and it will be able to benefit from growth in Russia and other emerging markets.”
Telenor owns 35.7 percent of VimpelCom and Altimo, the telecommunications division of Fridman’s Alfa Group, owns 31.4 percent, according to data compiled by Bloomberg. Billionaire Naguib Sawiris’s Weather Investment’s has 18.8 percent. Russia’s Anti-Monopoly Service is disputing Oslo-based Telenor’s right to increase its stake in VimpelCom with the purchase of shares from Sawiris’s companies.
Sales declined 4 percent to $5.75 billion, while earnings before interest, taxes, depreciation and amortization climbed 8 percent to $2.48 billion, the company said.
The “results were negatively impacted by U.S. dollar appreciation against operating currencies,” VimpelCom said.
VimpelCom increased its subscriber base by 8 percent to 208 million, adding customers in its Africa and Asia business unit and boosting fixed and mobile broadband services in Russia and Italy, the company said.
To contact the reporter on this story: Anatoly Temkin in St. Petersburg at atemkin@bloomberg.net
To contact the editor responsible for this story: James M. Gomez at jagomez@bloomberg.net
VimpelCom Delivers Solid Profitable Organic Growth In 2Q12
PR NewswirePress Release: VimpelCom Ltd. – 6 hours ago
AMSTERDAM, Aug. 15, 2012 /PRNewswire/ --
KEY RESULTS AND DEVELOPMENTS IN 2Q12*
Revenues of USD 5.7 billion, with organic1 growth of 4% YoY
EBITDA of USD 2.5 billion, up 8% organically YoY; double digit growth in Russia, Africa & Asia and CIS
Results negatively impacted by USD appreciation against operating currencies
Total mobile subscriber base increased 8% YoY2 to 208 million
Positive operational development continues in Business Unit Russia
Net income increased 83% YoY to USD 488 million
"VimpelCom Ltd." ("VimpelCom", "Company" or "Group") (VIP), a leading global provider of telecommunications services, today announces operating and financial results for the quarter ended June 30, 2012.
Read more ...
Big Boards - Top Losers Tue Aug 14 - Source: finviz.com
[ 10%+ losers ]
ENVI Envivio, Inc. 2.48 -56.49%
LPR Lone Pine Resources Inc. 1.34 -37.09%
GRPN Groupon, Inc. 5.51 -27.02%
GSV Gold Standard Ventures Corp 1.31 -26.82%
ROYL Royale Energy Inc. 2.14 -23.84%
SUMR Summer Infant, Inc. 2.51 -22.29%
LIVE LiveDeal, Inc. 4.93 -20.48%
EDS Exceed Company Ltd. 1.93 -14.22%
KIOR KiOR, Inc. 6.86 -14.04%
GOL GOL Linhas A 4.76 -12.66%
PPHM Peregrine Pharmaceuticals Inc. 2.52 -11.89%
OBCI Ocean Bio-Chem Inc. 1.88 -11.74%
TW Towers Watson & Co. 51.68 -11.73%
SGMS Scientific Games Corporation 6.20 -11.43%
NEON Neonode, Inc. 3.85 -11.09%
TGS Transportadora de Gas Del Sur S.A. 1.69 -11.05%
AMRS Amyris, Inc. 3.88 -10.80%
VTG Vantage Drilling Company 1.52 -10.59%
LIWA Lihua International, Inc. 4.21 -10.43%
http://stockcharts.com/c-sc/sc?s=ENVI&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LPR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=GRPN&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=GSV&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ROYL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SUMR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LIVE&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=EDS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=KIOR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=GOL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PPHM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=OBCI&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=TW&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SGMS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=NEON&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=TGS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=AMRS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=VTG&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LIWA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
Big Boards - Top Gainers Tue Aug 14 - Source: finviz.com
Top 25 charts posted.
20%+ gainers
CLNT Cleantech Solutions International, Inc. 3.38 37.40%
SATC Satcon Technology Corporation 1.47 19.51%
KORS Michael Kors Holdings Ltd. 49.33 16.48%
OFI Overhill Farms Inc. 4.61 15.83%
ARNA Arena Pharmaceuticals, Inc. 8.26 14.09%
CIE Cobalt International Energy, Inc. 23.63 13.72%
VELT Velti Plc 7.88 11.93%
BPZ BPZ Resources, Inc. 2.50 11.61%
ASTI Ascent Solar Technologies, Inc. 1.79 11.18%
ZIPR zipRealty Inc. 2.00 11.11%
PGRX Prospect Global Resources, Inc. 2.49 10.83%
ANW Aegean Marine Petroleum Network Inc. 6.88 10.79%
PLM Polymet Mining Corp. 1.14 10.68%
SGRP Spar Group Inc. 1.50 10.29%
MNST Monster Beverage Corporation 58.59 9.99%
COGO Cogo Group, Inc. 2.00 9.89%
EL Estee Lauder Companies Inc. 60.13 9.31%
PCRX Pacira Pharmaceuticals Inc. 17.00 9.11%
NSM Nationstar Mortgage Holdings Inc. 27.60 9.05%
VTSS Vitesse Semiconductor Corp. 2.60 8.79%
SGYP Synergy Pharmaceuticals, Inc. 4.06 8.56%
CBM Cambrex Corporation. 12.35 8.05%
XRM Xerium Technologies Inc. 4.04 8.02%
CSTE CaesarStone Sdot-Yam Ltd. 11.72 8.02%
CEL Cellcom Israel Ltd. 6.61 7.65%
LEAP Leap Wireless International Inc. 5.59 7.50%
PTNR Partner Communications Company Ltd. 3.61 7.44%
DRTX Durata Therapeutics, Inc. 8.44 7.38%
NLST Netlist Inc. 1.90 7.34%
UEC Uranium Energy Corp. 2.38 7.21%
VVUS VIVUS Inc. 23.24 7.00%
VIVO Meridian Bioscience Inc. 18.31 6.95%
TAT TransAtlantic Petroleum Ltd. 1.08 6.93%
PRSC Providence Service Corp. 10.43 6.86%
ARRY Array BioPharma, Inc. 4.87 6.80%
YGE Yingli Green Energy Holding Co. Ltd. 1.89 6.78%
AERL Asia Entertainment & Resources Ltd. 3.49 6.73%
SKS Saks Incorporated 11.52 6.18%
NQ NetQin Mobile Inc. 7.45 6.13%
PWRD Perfect World Co., Ltd. 10.94 6.11%
HK Halcon Resources Corporation 7.72 5.90%
SZYM Solazyme, Inc. 13.16 5.87%
NIHD NII Holdings Inc. 6.93 5.80%
SNSS Sunesis Pharmaceuticals Inc. 3.12 5.76%
CDXS Codexis, Inc. 2.45 5.60%
CBK Christopher & Banks Corporation 2.46 5.58%
TNK Teekay Tankers Ltd. 4.36 5.57%
MGIC Magic Software Enterprises Ltd. 4.29 5.41%
EMAN eMagin Corp. 4.13 5.36%
ASUR Asure Software, Inc. 7.50 5.34%
PATK Patrick Industries Inc. 12.35 5.29%
KCG Knight Capital Group, Inc. 2.99 5.28%
CZZ Cosan Ltd. 13.95 5.20%
HLSS Home Loan Servicing Solutions, Ltd. 15.23 5.11%
HMIN Home Inns & Hotels Management Inc. 24.14 5.00%
http://stockcharts.com/c-sc/sc?s=CLNT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SATC&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=KORS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=OFI&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ARNA&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CIE&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=VELT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=BPZ&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ASTI&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ZIPR&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PGRX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ANW&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PLM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SGRP&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=MNST&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=COGO&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=EL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PCRX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=NSM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=VTSS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SGYP&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CBM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=XRM&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CSTE&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CEL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
Big Boards scans - Tuesday Aug 14 Gainers
Top 20 charts posted.
20%+ gainers
None
10%-20% gainers
KORS 49.33 6.98 16.48%
ATPG 0.49 0.06 13.90%
VELT 7.88 0.84 11.92%
ANW 6.88 0.67 10.79%
5%-10% gainers
MNST 58.59 5.32 9.99%
COGO 2.00 0.18 9.89%
CEL 6.61 0.47 7.65%
LEAP 5.59 0.39 7.50%
VVUS 23.24 1.52 7.00%
ARRY 4.87 0.31 6.80%
AERL 3.49 0.22 6.73%
SKS 11.52 0.67 6.18%
KCG 2.99 0.15 5.28%
Others
PRSS 9.55 0.40 4.37%
MAKO 15.17 0.50 3.41%
ALC 7.24 0.23 3.28%
SVNT 0.98 0.03 3.16%
MTG 1.31 0.04 3.15%
NFLX 61.76 1.85 3.09%
NCIT 7.50 0.20 2.74%
SFUN 13.87 0.31 2.29%
LRN 20.40 0.44 2.20%
SOQ 0.98 0.02 2.08%
STS 4.18 0.08 1.95%
OMPI 13.23 0.25 1.93%
SM 47.44 0.79 1.69%
EDU 13.62 0.22 1.64%
AZC 2.68 0.04 1.52%
JCP 22.98 0.31 1.37%
VPHM 24.65 0.30 1.23%
CMVT 5.86 0.07 1.21%
JIVE 15.28 0.17 1.13%
ACOR 22.74 0.24 1.07%
AUO 3.01 0.03 1.01%
http://stockcharts.com/c-sc/sc?s=KORS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ATPG&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=VELT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ANW&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=MNST&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=COGO&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=CEL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=LEAP&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=VVUS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ARRY&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=AERL&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SKS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=KCG&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=PRSS&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=MAKO&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=ALC&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=SVNT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=MTG&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=NFLX&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
http://stockcharts.com/c-sc/sc?s=NCIT&p=D&yr=0&mn=6&dy=0&i=p85310988516&a=270624201&r=1342041056464
MYGN. results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 million and resulted in fiscal year 2012 revenue of $496.0 million, an increase of 23 percent over fiscal 2011. Fourth fiscal quarter diluted earnings per share were $0.34, an increase of 14 percent over the same period of the prior year. Fiscal 2012 diluted earnings per share equaled $1.30, an increase of 18 percent year-over-year.
http://finance.yahoo.com/news/myriad-genetics-reports-fourth-quarter-200500412.html
"Myriad achieved record revenue and operating profits last year," said Peter D. Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "We are committed to building on this strong performance in fiscal 2013 as we continue to execute on our strategic directives: to grow existing tests and markets, to expand internationally and to launch new tests, including companion diagnostics, across a diverse set of major disease indications."
Fourth Fiscal Quarter 2012 Results
Molecular diagnostic testing revenue in the fourth fiscal quarter equaled $127.5 million, an increase of 21 percent compared to the prior year period. Revenue from the Oncology segment equaled $87.0 million, an increase of 16 percent over the fourth fiscal quarter of 2011. Women's Health revenue totaled $40.5 million, an increase of 32 percent over the same period in the prior year.
Revenue from the BRACAnalysis(R) test, which represented 81.7 percent of total revenue in the fourth quarter, was $108.7 million, a 17 percent increase over the same period of the prior year.
Revenue from the COLARIS(R) and COLARIS AP(R) tests, which represented 8.7 percent of total revenue during the quarter, was $11.5 million, an increase of 51 percent compared to the same fiscal quarter of the prior year.
Myriad's other molecular diagnostic tests contributed $7.3 million to fourth quarter revenue, or 5.5 percent of total revenue, an increase of 47 percent over the same period in the prior year.
Companion diagnostic service revenue in the fourth fiscal quarter equaled $5.5 million and represented 4.1 percent of total company revenue. Revenue in the fourth fiscal quarter of 2011 equaled $2.0 million as the Company acquired this business in May 2011.
Operating income was $47.3 million, an increase of 13 percent from the prior year period. This level of operating income included the impact of increased investment in research and development to support existing molecular diagnostic tests and future products, as well as investments for international expansion and Myriad RBM.
Net income for the fourth fiscal quarter was $29.1 million, an increase of 12 percent over the $26.0 million reported in same period of the prior year.
During the quarter the Company repurchased 2.6 million shares or $61.0 million of its common stock, resulting in an average price of $23.70, under its previously announced stock repurchase program. Fourth fiscal quarter diluted weighted average shares outstanding were 86.3 million as compared to 88.1 million in the same period of the prior year.
Days sales outstanding for Myriad's accounts receivable improved to 41 days, compared with 43 days in the same period of the prior year and bad debt expense was 5.5 percent of total revenue.
Fiscal Year 2012 Results
Fiscal 2012 molecular diagnostic testing revenue equaled $472.4 million, an increase of 18 percent compared to the prior year. Revenue from the Oncology segment equaled $327.6 million, an increase of 16 percent over fiscal 2011. Women's Health revenue totaled $144.8 million, an increase of 24 percent over the prior year.
Revenue from the BRACAnalysis test was $405.5 million, an increase of 15 percent over the prior year.
Revenue from the COLARIS and COLARIS AP tests was $43.3 million, an increase of 48 percent compared to the prior year.
Myriad's other molecular diagnostic tests contributed $23.6 million to fiscal 2012 revenue, an increase of 32 percent over the prior year.
Companion diagnostic service revenue in the fiscal 2012 equaled $23.6 million. Revenue in fiscal 2011 equaled $2.0 million as the Company acquired this business in May 2011.
Operating income was $180.3 million, an increase of 14 percent from the prior year. Investment in research and development increased 54 percent versus the prior year and investments in the Company's international expansion and Myriad RBM lead to a 23 percent increase in sales, general and administrative expense.
Net income for the fiscal year was $112.2 million, an increase of 11 percent over the $100.7 million reported in the prior year.
During the fiscal year the Company repurchased 5.7 million shares or $128.5 million of its common stock, resulting in an average price of $22.59, under its previously announced stock repurchase program. Diluted weighted average shares outstanding were 86.5 million as compared to 91.7 million in the prior year.
The Company ended the fiscal year with $454.2 million in cash, cash equivalents and marketable investment securities. The Company has no debt or other restrictions on its cash.
Business Highlights of Fiscal Year 2012
Entered into a loan and acquisition option agreement with Crescendo Bioscience, under which Myriad made a $25 million strategic debt investment in Crescendo to secure an exclusive, three-year option to acquire the company. The potential acquisition of Crescendo Bioscience, if completed, would expand the Company's portfolio of molecular diagnostic products to include products for autoimmune disorders, such as rheumatoid arthritis.
Established subsidiaries and sales offices in Germany, France, Spain, Italy and Switzerland, as well as laboratory operations in Germany.
Published a study in the British Journal of Cancer which highlighted the ability of the Company's Prolaris(R) test to significantly predict prostate cancer aggressiveness and consequent death from the disease.
Presented a study at the 27th Annual EAU Congress, and the 2012 Genitourinary Cancers Symposium, which concluded that the Company's Prolaris test demonstrated significant and unique prognostic ability in men who had undergone radical prostatectomy and accurately predicted their elevated risk for prostate cancer recurrence.
Presented a study at the 2012 ASCO Annual Meeting that demonstrated that the Company's lung cancer prognostic test significantly predicted cancer-specific death in early stage adenocarcinoma lung cancer patients.
Acquired an exclusive license to intellectual property covering the analysis of the RAD51C gene for risk of hereditary breast and ovarian cancer.
Entered into companion diagnostic agreements with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., and Pharma Mar to conduct companion diagnostic testing for their clinical trials.
Presented a study at the San Antonio Breast Cancer Symposium which demonstrated that the BRACAnalysis test is a cost-effective intervention for a much larger group of unaffected women than current guidelines would suggest.
Fiscal Year 2013 Outlook
The Company expects fiscal year 2013 total revenue of $550 million to $565 million and diluted earnings per share of $1.44 to $1.48. These projections are forward looking statements and are subject to the risks summarized in the safe harbor statement at the end of this press release. The Company will provide further detail on its business outlook during the conference call it is holding today to discuss its fiscal results for the fourth fiscal quarter and fiscal year 2012 financial results.
Resting side-long. COBR. (no mod).
per 10-Q: 8/13/12
Net earnings for the current quarter improved $385,000, or $.06 per share, from 2011’s second quarter. For the three months ending June 30, 2012 the Company reported net earnings of $902,000, or $.14 per share, compared to earnings of $517,000, or $.08 per share, for the comparable prior year period.
Investor Relations.
http://phx.corporate-ir.net/phoenix.zhtml?c=87273&p=irol-IRHome
I agree - I missed out on getting in at the bottom but congrats!
Current Tankers:
AERG (-17.35%)
CXM (-12.62%)
ENVI (-54.21%)
GRPN (-23.05%)
GSV (-16.21%)
LPR (-28.17%)
MKTS (-33.33%)
ROYL (-17.79%)
SUMR (-24.77%)
TW (-10.76%)
WEST (-18.59%)
Home Depot Earnings Beat Forecasts, Ups Guidance
Published: Tuesday, 14 Aug 2012
By: Reuters
Home Depot raised its fiscal-year earnings outlook on Tuesday as tight cost controls helped the world's largest home improvement chain offset sales weakness and beat Wall Street's profit estimates in the latest quarter.
The company's second quarter, which ended on July 29, is typically the most important selling period for home improvement chains, but unseasonably warm weather early in the year pulled some demand into the first quarter.
Net earnings rose to $1.53 billion, or $1.01 a share, in the quarter from $1.36 billion, or 86 cents a share, a year earlier. Analysts on average were expecting a profit of 97 cents a share, according to Thomson Reuters I/B/E/S.
Sales rose 1.7 percent to $20.57 billion, but missed the analysts' average estimate of $20.74 billion. Operating expenses fell 2.7 percent to $4.46 billion.
Shares of Home Depot [HD 54.48 1.66 (+3.14%) ] rose 1.3 percent to $53.50 in trading before the market opened.
Home Depot has benefited from its recent efforts to improve distribution and customer service. It has been quicker to cut costs than rival Lowe's [LOW 26.42 -0.13 (-0.49%) ] and in some cases has gotten a boost as housing markets have rebounded in regions where it has a heavy presence.
A return to more localized marketing and merchandising has also helped Home Depot.
In the second quarter, sales at stores open at least a year rose 2.1 percent globally, including a 2.6 percent increase in the United States.
While Home Depot's results exceeded his estimates, Janney Capital Markets analyst David Strasser said he was less optimistic about same-store sales growth in the back half of the year, citing consumer spending trends.
The company's operating performance remains impressive, but that is largely priced into the stock, Strasser said...
SOQ: I was off by 1 cent on my call...originally thought .98 would be the high :)
SOQ Update: Sold partial for 8% gains at .99! But...sadly the rest at .96...oh well, still up from .92 :)
investorshub.advfn.com/boards/read_msg.aspx?message_id=78485463
AAPL Update: $635.30 new high, which means my $640 target is very close!
MGM Update: Sold partial for 8% gains but still holding the majority for the short term.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78377313&txt2find=mgm
Successful Trades: 15/17 = 88%
*Refer to the Intro/iBox for more information.
Early movers ...
Symbol %Change Last High Change
VELT +13.62% 8.00 8.61 +0.959
KORS +13.48% 48.06 49.00 +5.71
SVNT +13.16% 1.075 1.10 +0.125
KIOR +10.65% 8.83 8.96 +0.85
STS +8.51% 4.4489 4.66 +0.3489
ATPG +7.21% 0.4612 0.50 +0.031
ANW +4.51% 6.49 6.50 +0.28
ARRY +2.41% 4.67 4.84 +0.11
VVUS +2.21% 22.201 22.49 +0.481
AUO +2.01% 3.04 3.05 +0.06
SOQ Update: Sold partial for 8% gains at .99! But...sadly the rest at .96...oh well, still up from .92 :)
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=78485463
Morning Dan, markets are up...hopefully a great day for us all lol.
Followers
|
2
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
531
|
Created
|
07/24/12
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |